This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Abbott-Exact Sciences deal to be reviewed by Australian antitrust regulator

( February 2, 2026, 06:43 GMT | Official Statement) -- MLex Summary: Global healthcare company Abbott Laboratories’ proposal to acquire Exact Sciences will be reviewed under the new mandatory merger regime, the Australian competition watchdog said Monday. In a statement, the Australian Competition & Consumer Commission said that Abbott, through subsidiary Badger Merger Sub I, proposes to acquire all of the shares in Exact Sciences under an agreement and plan of merger. Both companies, headquartered in the US, supply oncological diagnostic products in Australia.Statement follows. The questionnaire is attached....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections